Liu Chun-Yu, Wu Chia-Yun, Petrossian Karineh, Huang Tzu-Ting, Tseng Ling-Ming, Chen Shiuan
Division of Medical Oncology, Department of Oncology, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Department of Cancer Biology, Beckman Research Institute of the City of Hope, United States.
J Steroid Biochem Mol Biol. 2017 Sep;172:166-175. doi: 10.1016/j.jsbmb.2017.07.001. Epub 2017 Jul 3.
Endocrine resistance remains a challenge and an unmet need for managing hormone receptor-positive breast cancer. The mechanisms of endocrine resistance are multifaceted and are likely to evolve over time following various single or combination therapies. The purpose of this review article is to provide general understanding of molecular basis of endocrine resistance of breast cancer and to offer comprehensive review on current treatment options and potential new treatment strategies for endocrine resistant breast cancers. Last but not the least, we discuss current challenges and future directions for management of endocrine resistant breast cancers.
内分泌耐药仍然是激素受体阳性乳腺癌治疗面临的一项挑战和未被满足的需求。内分泌耐药机制是多方面的，并且在接受各种单一或联合治疗后可能会随时间演变。这篇综述文章的目的是提供对乳腺癌内分泌耐药分子基础的总体认识，并对内分泌耐药乳腺癌的当前治疗选择和潜在新治疗策略进行全面综述。最后但同样重要的是，我们讨论了内分泌耐药乳腺癌治疗的当前挑战和未来方向。
